Back to News
Jan 9, 2026 8:00 PM

Beta Bionics Key KPI Miss Targets, Analyst Flags Valuation Risks

Diabetes management solutions provider, Beta Bionics Inc. (NASDAQ:BBNX), on Thursday reported preliminary fourth-quarter 2025 results showing strong revenue growth, driven by rapid expansion in its Pharmacy Benefit Plan channel and a growing installed user base for its diabetes management technology.

The company said net sales for the quarter are expected to reach at least $32 million, versus the consensus of $28.19 million, representing a year-over-year increase of at least 56%.

Sales through the Durable Medical Equipment (DME) channel are expected to total at least $22.3 million, up at least 23%. Pharmacy Benefit Plan (PBP) channel revenue is expected to reach at least $9.7 million, compared with $2.4 million a year ago.

The company expects the installed base to exceed 35,000 users, more than double the 15,298 reported a year earlier.

New patient starts ...